Indian Pharmaceutical & Ayurvedic Business Seminar in Kyiv

59
Pharmaceutical Conference in Kyiv

At the end of November, Pharmaceutical Export Promotion Council of India visited Kyiv. It was the reason for business seminar on cooperation with Indian pharmaceutical and ayurvedic companies.

During the visit to Ukraine, local experts met with representatives of more than 23 Indian pharmaceutical and Ayurvedic companies. The purpose of the event was exchanging business opportunities, statistics and discussing bilateral trade in the pharmaceutical sector. The business seminar in Kyiv was attended by representatives of leading Indian pharmaceutical companies and honored guests: representatives of state health authorities of Ukraine, international organizations, profile organizations, and representatives of domestic pharmaceutical business.

0 0
India occupies an important sector of the world pharmaceutical market: India's share in the global generic market is 4.3%, over 55% of India's exports are aimed at the high-regulated markets. Besides, India supplies 70% of medicines distributed by global non-governmental organizations.

«During the last decade (2008-2017), the US Food and Drug Administration approved 5020 Drug Registration Applications under the abridged procedure, of which Indian pharmaceutical companies received approvals for 1,695 applications - almost 34%. At the same time, the USFDA approved 846 Drug Registration Applications under the abridged procedure for 2017, the largest number in a decade. Indian pharmaceutical companies have received 304 approvals, which is about 36% of the total approvals by the USFDA,» - noted Raghuveer Kini, Executive Director of PHARMEXCIL.

Photos provided by Indian Pharmaceutical Manufacturers Organisation.

Read Also

Syngenta in Ukraine press conference

Syngenta: Pioneering Agroinsurance in Ukraine

On November 23, Syngenta in Ukraine in partnership with the PZU insurance company presented an updated program of index insurance "MeteoZakhyst" for 2019 and the results of work for the previous three...

Partner news

Fresh

View More

On our site we use cookies (and these are not cookies), which make it more convenient for each user. By visiting the pages of the site, you agree to our Privacy Policy. For more information on the Policy and what cookies are needed for and how you can stop collecting cookies, click here.

Ok